

REMARKS

Claims 1–15 are pending. Claims 1 and 15 are currently amended.

The Applicant respectfully requests reconsideration and withdrawal of the rejection of claims 1–3, 7–9, and 13–15 under 35 U.S.C. 112, first and second paragraphs, because (1) the use of the term “imino” (*e.g.*, in definition for D) in claim 1 has been clarified (*i.e.*, both bonds are on the N), and (2) the claimed method of claim 15 is for treating *inter alia* “allograft transplantation osteoporosis” and “rheumatoid arthritis”.

The Applicant respectfully requests reconsideration and withdrawal of the objection to the Abstract of the Specification in light of the foregoing amendment thereto.

Respectfully submitted,

/THOMAS BLANKINSHIP/

Thomas Blankinship
Reg. No. 39,909

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 791-6615

December 14, 2005